LINTONPHARM
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Breker Verification Systems and Frontgrade Gaisler Collaborate on High-Reliability RISC-V Fault Tolerant Processor Core20.11.2025 09:00:00 CET | Press release
Breker Verification Systems, whose portfolio solves challenges across the functional verification process for large, complex semiconductors and Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions today confirmed its RISC-V functional verification solutions were pivotal for verification of the NOEL-V, one of Frontgrade Gaisler’s fault-tolerant RISC-V processor IP cores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120600508/en/ “The development of Frontgrade Gaisler’s IP cores is guided by a philosophy that does not tolerate design issues,” notes Jan Andersson, Director of Engineering at Frontgrade Gaisler. “This demands the most robust verification environment, something Breker’s verification solution has contributed to improve, with its broad range of tests and in-depth corner case coverage.” The ultra-high verification coverage afforded by Brek
Yagi & Co., Ltd.: Exhibiting for the first time at ISPO Munich 2025, the world's largest trade fair for sports goods, based in Germany20.11.2025 09:00:00 CET | Press release
We propose textiles and products utilising original materials developed by our Materials Division specifically to address environmental, health, and heat countermeasures, primarily within the sports and outdoor sectors. Yagi & Co., Ltd. (TOKYO:7460) (https://www.yaginet.co.jp/en/index.html) will be exhibiting for the first time at ISPO Munich, held in Munich, Germany, over three days from Sunday 30th November to Tuesday 2nd December this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119473772/en/ Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special technology to finely crush the lava rock that lies underground at Mt. Fuji for weaving into fibers. This brand of materials enables the creation of new pr
Verne and Nscale Announce 15MW AI Infrastructure Deployment to Accelerate Sustainable AI Infrastructure Growth in the Nordics20.11.2025 09:00:00 CET | Press release
Nscale selects Verne for major liquid-cooled GPU deployment to expand Europe’s AI capacity Verne, the leading provider of low-carbon high-performance data centres across the Nordics, has signed a 15-megawatt agreement with Nscale, the hyperscaler engineered for AI. This collaboration marks a significant step in expanding sustainable AI capacity in Europe. The agreement will feature approximately 4,600 NVIDIA Blackwell Ultra GPUs deployed across Verne’s Icelandic campus throughout 2026. The configuration will be 85 percent liquid-cooled and 15 percent air-cooled, optimised for efficiency and density within Verne’s existing infrastructure. This project is one of the region’s largest liquid-cooled GPU installations, setting a new standard for sustainable high-performance computing by reducing energy use and environmental impact. Dominic Ward, CEO, Verne, said: “The pace of change in AI infrastructure is extraordinary. As the demand for GPU capacity accelerates, availability of clean, rene
Lenovo Group: Second Quarter Financial Results 2025/2620.11.2025 00:45:00 CET | Press release
Lenovo delivers record quarterly results, marking significant progress in hybrid AI Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported record results for the second quarter of fiscal year 2025/26, with overall group revenue reaching an all-time high of US$20.5 billion, up 15% year-on-year. Adjusted net income[1] grew 25% year-on-year to US$512 million, and adjusted net income margin expanded to 2.5%, driven by higher revenues. Together, these reflect the strength of the Group’s operational performance as they exclude the impact of non-cash fair value loss on warrants, notional interest on convertible bonds, and other non-cash items. The Group delivered double-digit year-on-year revenue growth across all main business groups and sales geographies. The AI-related revenue mix increased by 13 percentage points year-on-year, accounting for 30% of the Group’s total revenue this quarter. The growth was driven by high-double-digit revenue
OCP Announces Date of Third Quarter and Nine-Month 2025 Earnings19.11.2025 22:05:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2025 results on Tuesday, November 25, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 3:00 p.m. Morocco (GMT+1), and 2:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2025 results at 10:00 a.m. EDT, 4:00 p.m. Morocco (GMT+1), and 3:00 p.m. London time (GMT) on Tuesday, November 25, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom